Is Hims & Hers' $1.15 Billion Eucalyptus Acquisition a Game-Changer for Global Telehealth

Related Articles

Hims & Hers's GLP-1 Revenue Surge Erodes Core Profitability

2 months ago

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

7 months ago

Udine's High-Beta Bet: Navigating Volatility in Reddit and Hims & Hers

2 months ago

Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

2 months ago

Category

You may also like

Stock News•1 day ago

Hims & Hers Health: The Bullish Case Is Hard To Forecast, But It Is Asymmetrical

Hims & Hers Health was rated buy with a $41 fair value versus $29.81, as the market discounts regulatory risk and the Novo partnership could add over 50% new subscribers annually.

HIMS

Share

Stock News•1 months ago

Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide

Hims & Hers launched its Hims brand in Australia today, rebranding Eucalyptus' men's health platform Pilot nationwide. The move follows its acquisition of Eucalyptus earlier this year, with existing p...

HIMS

Share

Stock News•2 months ago

HIMS Q2 Earnings Call Focuses on AI and Global Expansion

Hims & Hers raised its 2026 revenue outlook after AI boosted engagement and specialty care expanded, while Eucalyptus extended international reach despite margin pressure.

HIMS

Share